SITE011-0115

SITE011 (ITA) › SITE011-0115

SITE011-0115

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2026-01-21

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 167); relationship: NOT RELATED

severe assessed

Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 108); relationship: RELATED

mild assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-28 (study day 97); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-22 (study day 91); relationship: not assessed

moderate assessed

Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-10-16 (study day 85); relationship: not assessed

moderate assessed

Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 70); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.